Subcutaneous rituximab induction followed by short rituximab maintenance to improve progression-free survival in patients with low-tumor burden follicular lymphoma: Final results of FLIRT phase III trial, a LYSA study.

被引：0
|
作者：
Cartron, Guillaume
Bachy, Emmanuel
Tilly, Herve
Daguindau, Nicolas
Pica, Gian Matteo
Bijou, Fontanet
Mounier, Christiane
Clavert, Aline
Damaj, Gandhi Laurent
Slama, Borhane
Casasnovas, Olivier
Houot, Roch
Bouabdallah, Krimo
Sibon, David
Fitoussi, Olivier
Morineau, Nadine
Morschhauser, Franck
Xerri, Luc
Tarte, Karin
Pranger, Delphine
机构：
[1] CHU Montpellier, Montpellier, France
[2] Ctr Hospitalier Lyon Sud, Lyon, France
[3] Ctr Henri Becquerel, Rouen, France
[4] CH Annecy Genevois, Annecy, France
[5] CH Chambery, Chambery, France
[6] Inst Bergoni, Bordeaux, France
[7] Inst Cancerol Lucien Neuwirth, St Priest En Jarez, France
[8] CHU Angers, Angers, France
[9] CHU Amiens, Amiens, France
[10] CH Avignon, Avignon, France
[11] CHU Dijon, Dijon, France
[12] Hop Pontchaillou CHU Rennes, Rennes, France
[13] CHU Bordeaux, Bordeaux, France
[14] Hop Necker Enfants Malad, Paris, France
[15] Polyclin Bordeaux Nord, Bordeaux, France
[16] CH Roche Yon, La Roche Sur Yon, France
[17] CHU Lille, Lille, France
[18] Inst Paoli Calmettes, Marseille, France
[19] CHU Rennes, Rennes, France
[20] CH Charleroi, Charleroi, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7512
引用
收藏
页数：1
相关论文
共 32 条
  • [1] Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study
    Cartron, Guillaume
    Bachy, Emmanuel
    Tilly, Herve
    Daguindau, Nicolas
    Pica, Gian-Matteo
    Bijou, Fontanet
    Mounier, Christiane
    Clavert, Aline
    Damaj, Gandhi Laurent
    Slama, Borhane
    Casasnovas, Olivier
    Houot, Roch
    Bouabdallah, Krimo
    Sibon, David
    Fitoussi, Olivier
    Morineau, Nadine
    Herbaux, Charles
    Gastinne, Thomas
    Fornecker, Luc-Matthieu
    Haioun, Corinne
    Launay, Vincent
    Araujo, Carla
    Benbrahim, Omar
    Sanhes, Laurence
    Gressin, Remy
    Gonzalez, Hugo
    Morschhauser, Franck
    Ternant, David
    Xerri, Luc
    Tarte, Karin
    Pranger, Delphine
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3523 - +
  • [2] Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study (vol 41, pg 3523, 2023)
    Cartron
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (25) : 4187 - 4187
  • [3] Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study
    Bachy, Emmanuel
    Seymour, John F.
    Feugier, Pierre
    Offner, Fritz
    Lopez-Guillermo, Armando
    Belada, David
    Xerri, Luc
    Catalano, John V.
    Brice, Pauline
    Lemonnier, Francois
    Martin, Alejandro
    Casasnovas, Olivier
    Pedersen, Lars M.
    Dorvaux, Veronique
    Simpson, David
    Leppa, Sirpa
    Gabarre, Jean
    da Silva, Maria G.
    Glaisner, Sylvie
    Ysebaert, Loic
    Vekhoff, Anne
    Intragumtornchai, Tanin
    Le Gouill, Steven
    Lister, Andrew
    Estell, Jane A.
    Milone, Gustavo
    Sonet, Anne
    Farhi, Jonathan
    Zeuner, Harald
    Tilly, Herve
    Salles, Gilles
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (31) : 2815 - +
  • [4] Bendamustine and rituximab in elderly patients with low-tumour burden follicular lymphoma. Results of the LYSA phase II BRIEF study
    Gyan, Emmanuel
    Sonet, Anne
    Brice, Pauline
    Anglaret, Bruno
    Laribi, Kamel
    Fruchart, Christophe
    Tilly, Herve
    Araujo, Carla
    Soubeyran, Pierre
    Gonzalez, Hugo
    Morineau, Nadine
    Nicolas-Virelizier, Emmanuelle
    Ghesquieres, Herve
    Salles, Bruno
    Bouabdallah, Reda
    Orfeuvre, Hubert
    Fahri, Jonathan
    Couturier, Olivier
    Xerri, Luc
    Feugier, Pierre
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 183 (01) : 76 - 86
  • [5] COMPARISON OF SUBCUTANEOUS AND INTRAVENOUS RITUXIMAB IN THE MAINTENANCE SETTING: UPDATED SAFETY RESULTS OF THE PHASE III SABRINA STUDY IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Davies, A.
    Mihaljevic, B.
    Mercadal, S.
    Mihaylov, G.
    Leppa, S.
    Cotting, D.
    Munoz, F. J.
    Veenstra, K.
    Berthillon, N.
    Barrett, M.
    MacDonald, D.
    HAEMATOLOGICA, 2015, 100 : 271 - 272
  • [6] Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
    Kwak, Larry W.
    Sancho, Juan-Manuel
    Cho, Seok-Goo
    Nakazawa, Hideyuki
    Suzumiya, Junji
    Tumyan, Gayane
    Kim, Jin Seok
    Menne, Tobias
    Mariz, Jose
    Ilyin, Nikolai
    Jurczak, Wojciech
    Lopez Martinez, Aurelio
    Samoilova, Olga
    Zhavrid, Edvard
    Yanez Ruiz, Eduardo
    Trneny, Marek
    Popplewell, Leslie
    Ogura, Michinori
    Kim, Won-Seog
    Lee, Sang Joon
    Kim, Sung Hyun
    Ahn, Keum Young
    Buske, Christian
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (02): : 89 - 97
  • [7] Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study
    Hochster, Howard
    Weller, Edie
    Gascoyne, Randy D.
    Habermann, Thomas M.
    Gordon, Leo I.
    Ryan, Theresa
    Zhang, Lijun
    Colocci, Natalia
    Frankel, Stanley
    Horning, Sandra J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1607 - 1614
  • [8] Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma:: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Dreyling, M.
    Forstpointner, R.
    Gramatzki, M.
    Boeck, H.
    Haenel, M.
    Seymour, J.
    Planker, M.
    Duehrsen, U.
    Wilms, K.
    Unterhalt, M.
    Hiddemann, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 422S - 422S
  • [9] Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group
    Le Gouill, Steven
    Thieblemont, Catherine
    Oberic, Lucie
    Moreau, Anne
    Bouabdallah, Krimo
    Gyan, Emmanuel
    Damaj, Gandhi
    Ribrag, Vincent
    Feugier, Pierre
    Casasnovas, Olivier
    Zerazhi, Hacene
    Haioun, Corinne
    Tilly, Herve
    Tournilhac, Olivier
    Maisonneuve, Herve
    Solal-Celigny, Philippe
    Fornecker, Luc Mathieu
    Van Den Neste, Eric W.
    Canioni, Danielle
    Salles, Gilles
    Lamy, Thierry
    Bene, Marie-Christine
    Gressin, Remy
    Hermine, Olivier
    BLOOD, 2016, 128 (22)
  • [10] Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study
    Marcus, Robert E.
    Davies, Andrew J.
    Ando, Kiyoshi
    Klapper, Wolfram
    Opat, Stephen
    Owen, Carolyn J.
    Phillips, Elizabeth H.
    Sangha, Randeep
    Schlag, Rudolf
    Seymour, John F.
    Townsend, William
    Trneny, Marek
    Wenger, Michael K.
    Fingerle-Rowson, Gunter
    Rufibach, Kaspar
    Moore, Tom
    Herold, Michael
    Hiddemann, Wolfgang
    BLOOD, 2016, 128 (22)
1234